Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease

Picozzi, Stefano; Marenghi, Carlo; Ricci, Cristian; Bozzini, Giorgio; Casellato, Stefano; Carmignani, Luca
January 2014
Surgical Endoscopy;Jan2014, Vol. 28 Issue 1, p116
Academic Journal
Background: Urologists have not reached a consensus regarding the pre-, intra-, and postoperative management of patients taking antiplatelet agents. This study aimed to evaluate the clinical course of patients receiving antithrombotic monotherapy with acetylsalicylic acid (ASA) 100 mg who underwent transurethral resection of bladder cancer. Methods: This study was designed to compare the surgical outcomes for 108 transurethral resections of bladder cancer performed for patients taking antiplatelet therapy and for 105 procedures performed for patients who had never taken antiplatelet agents before surgery. Antiaggregant therapy was maintained according to criteria evaluated by a urologist, surgeon, anesthesiologist, and cardiologist. Variables were described using the mean as the location index and using standard deviation as a dispersion index if continuous percentages were used elsewhere. Group comparisons were performed using the t test or the chi-square test for categorical data, and Fisher's exact test was used where appropriate. Results: The mean operative time for patients taking ASA was 31 min (range 10-65 min), whereas it was 26 min (range 5-60 min) for control subjects. The difference between pre- and postoperative hemoglobin values was −0.6 g/dl in the group receiving antiplatelet therapy and −0.8 g/dl in the control group ( p = 0.0720). Transfusional support was required during four procedures performed for patients taking antiplatelet therapy and during two procedures for the control group ( p = 0.242). No adverse cardiac events or anesthesia-related complications occurred. Three patients in the treatment group and two patients in the control group required reintervention to ensure hemostasis during the postoperative period. None of the patients in either group underwent rehospitalization for hematuria after leaving the hospital. Conclusion: The current results suggest that continued use of anti-aggregant monotherapy does not increase the risk of overall bleeding or reintervention for patients undergoing transurethral resection of bladder neoplasms and that suspending aspirin before such a procedure is therefore unnecessary.


Related Articles

  • Patterns of Antiplatelet and Anticoagulant Agents Use in Urological Inpatients and Their Perception of Adverse Reactions. Anastasiou, Ioannis; Mihalakis, Anastasios; Mygdalis, Vassilios; Koutalellis, George; Adamakis, Ioannis; Constantinides, Constantinos; Mitropoulos, Dionisios // Surgical Science;Apr2012, Vol. 3 Issue 4, p200 

    Purpose: To evaluate the rate of any type of anticoagulant drug use in urological inpatients and patients awareness of their effect on coagulation. Material and Methods: This observational study was conducted prospectively in a cohort of 193 consecutive urological inpatients who were asked to...

  • Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. Descazeaud, Aurélien; Robert, Gregoire; Lebdai, Souhil; Bougault, Alain; Azzousi, Abdel; Haillot, Olivier; Devonec, Marian; Fourmarier, Marc; Saussine, Christian; Barry-Delongchamps, Nicolas; la Taille, Alexandre // World Journal of Urology;Apr2011, Vol. 29 Issue 2, p211 

    im: To assess the impact of oral anticoagulation (OA) on morbidity of transurethral resection of the prostate (TURP). OA included warfarin and platelet aggregation inhibitors (PAI). Patients and Method: Multicenter analysis of patients operated for symptomatic benign prostatic hyperplasia (BPH)...

  • Aspirin/clopidogrel.  // Reactions Weekly;Oct2014, Vol. 1521 Issue 1, p36 

    An abstract to the article "A cautionary tale on the use of antiplatelet treatment following TURP," by A. M. Murray and colleagues is presented.

  • Perioperative Antiplatelet Therapy. CHASSOT, PIERRE GUY; MARCUCCI, CARLO; DELABAYS, ALAIN; SPAHN, DONAT R. // American Family Physician;12/15/2010, Vol. 82 Issue 12, p1484 

    Aspirin is recommended as a lifelong therapy that should never be interrupted for patients with cardiovascular disease. Clopidogrel therapy is mandatory for six weeks after placement of bare-metal stents, three to six months after myocardial infarction, and at least 12 months after placement of...

  • Antithrombotics/paclitaxel/sirolimus.  // Reactions Weekly;9/25/2010, Issue 1320, p12 

    The article describes a case of fatal renal haemorrhage in a 54-year-old man following triple antiplatelet therapy with aspirin, clopidogrel and cilostazol, and oral anticoagulation therapy with warfarin after recurrent coronary stent thrombosis following drug-eluting and bare-metal stent...

  • PERIOPERATIVE MANAGEMENT OF ANTITHROMBOTIC THERAPY IN CARDIOVASCULAR PATIENTS. Nuttall, Marc T.; Rodgers, George M. // Methodist DeBakey Cardiovascular Journal;Dec2011, Vol. 7 Issue 4, p10 

    Many patients with underlying cardiovascular disease require long-term anticoagulation. The perioperative or periprocedural management of patients who require temporary interruption of anticoagulant or antiplatelet medications is a common and often challenging clinical problem.1 It requires a...

  • A Review of Antithrombotic Therapy and the Rationale and Design of the Randomized Edoxaban in Patients With Peripheral Artery Disease (ePAD) Trial Adding Edoxaban or Clopidogrel to Aspirin After Femoropopliteal Endovascular Intervention. Tangelder, Marco J. D.; Nwachuku, Chuke E.; Jaff, Michael; Baumgartner, Iris; Duggal, Anil; Adams, George; Ansel, Gary; Grosso, Michael; Mercuri, Michele; Shi, Minggao; Minar, Erich; Moll, Frans L. // Journal of Endovascular Therapy (Sage Publications Inc.);Apr2015, Vol. 22 Issue 2, p261 

    Compared with the coronary setting, knowledge about antithrombotic therapies after endovascular treatment (EVT) is inadequate in patients with peripheral artery disease (PAD). Based on a review of trials and guidelines, which is summarized in this article, there is scant evidence that...

  • Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Veitch, Andrew M.; Vanbiervliet, Geoffroy; Gershlick, Anthony H.; Boustiere, Christian; Baglin, Trevor P.; Smith, Lesley-Ann; Radaelli, Franco; Knight, Evelyn; Gralnek, Ian M.; Hassan, Cesare; Dumonceau, Jean-Marc // Gut;Mar2016, Vol. 65 Issue 3, p374 

    The risk of endoscopy in patients on antithrombotics depends on the risks of procedural haemorrhage versus thrombosis due to discontinuation of therapy. P2Y12 receptor antagonists (clopidogrel, prasugrel, ticagrelor) For low-risk endoscopic procedures we recommend continuing P2Y12 receptor...

  • Antithrombotic therapy of patients with atrial fibrillation discharged after major non-cardiac surgery. 1-year follow-up. Sub-analysis of PRAGUE 14 study. Ondrakova, Martina; Motovska, Zuzana; Waldauf, Petr; Knot, Jiri; Havluj, Lukas; Bittner, Lukas; Bartoska, Radek; Gűrlich, Robert; Krbec, Martin; Dzupa, Valer; Grill, Robert; Widimsky, Petr // PLoS ONE;5/24/2017, Vol. 12 Issue 5, p1 

    Background: The study investigated the discharge antithrombotic medication in patients with atrial fibrillation (AF) after major non-cardiac surgery and the impact on one-year outcomes. Methods: A subgroup of 366 patients (mean age 75.9±10.5 years, women 42.3%, acute surgery 42.9%)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics